Sunshine Biopharma Inc. (NASDAQ:SBFM) shares traded -3.03% lower at $0.64 on Wall Street last session.
SBFM stock price is now -20.36% away from the 50-day moving average and -57.91% away from the 200-day moving average. The market capitalization of the company currently stands at $14.90M.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
.
In other news, Sebaaly Camille, CFO/Secretary bought 30,000 shares of the company’s stock on Nov 30. The stock was bought for $22,905 at an average price of $0.76. Upon completion of the transaction, the CFO/Secretary now directly owns 174,465 shares in the company, valued at $0.11 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 03, CFO/Secretary Sebaaly Camille bought 25,000 shares of the business’s stock. A total of $30,500 was incurred on buying the stock at an average price of $1.22. This leaves the insider owning 144,465 shares of the company worth $92457.6. A total of 17.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SBFM stock. A new stake in Sunshine Biopharma Inc. shares was purchased by TWO SIGMA INVESTMENTS, LP during the first quarter worth $24,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP invested $9,000 in shares of SBFM during the first quarter. In total, there are 18 active investors with 2.00% ownership of the company’s stock.
Sunshine Biopharma Inc. (NASDAQ: SBFM) opened at $0.6501 on Friday. During the past 12 months, Sunshine Biopharma Inc. has had a low of $0.62 and a high of $15.50. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 85.10, and a quick ratio of 84.50. The fifty day moving average price for SBFM is $0.7909 and a two-hundred day moving average price translates $1.5073 for the stock.
The latest earnings results from Sunshine Biopharma Inc. (NASDAQ: SBFM) was released for Jun, 2022. The company reported revenue of $0.13 million for the quarter, compared to $50000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 166.0 percent.
Sunshine Biopharma Inc.(SBFM) Company Profile
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
